106 related articles for article (PubMed ID: 8822588)
41. Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.
Chen Y; Yang S; Yao W; Zhu H; Xu X; Meng G; Zhang W
PLoS One; 2014; 9(5):e98483. PubMed ID: 24852754
[TBL] [Abstract][Full Text] [Related]
42. Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells.
Togawa M; Haneda M; Araki S; Sugimoto T; Isono M; Hidaka H; Yasuda H; Kashiwagi A; Kikkawa R
Eur J Pharmacol; 1997 Oct; 336(2-3):291-4. PubMed ID: 9384245
[TBL] [Abstract][Full Text] [Related]
43. Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway.
Kamio K; Liu X; Sugiura H; Togo S; Kobayashi T; Kawasaki S; Wang X; Mao L; Ahn Y; Hogaboam C; Toews ML; Rennard SI
Am J Respir Cell Mol Biol; 2007 Jul; 37(1):113-20. PubMed ID: 17363776
[TBL] [Abstract][Full Text] [Related]
44. Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors.
Niiya K; Nsimba M; Hayashi T; Sakuragawa N
Thromb Res; 1992 Feb; 65(3):311-21. PubMed ID: 1631798
[TBL] [Abstract][Full Text] [Related]
45. [Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue].
Nishio S; Kurumatani H
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):123-30. PubMed ID: 11233303
[TBL] [Abstract][Full Text] [Related]
46. Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Osada H; Kono T; Miwa K; Yamada C
Int J Cancer; 1996 Jan; 65(2):178-85. PubMed ID: 8567114
[TBL] [Abstract][Full Text] [Related]
47. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects.
Nony P; Ffrench P; Girard P; Delair S; Azoulay S; Girre JP; Dechavanne M; Boissel JP
Can J Physiol Pharmacol; 1996 Aug; 74(8):887-93. PubMed ID: 8960377
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
[TBL] [Abstract][Full Text] [Related]
49. Beneficial effects of beraprost sodium, a stable prostacyclin analogue, in diabetic cardiomyopathy.
Ueno Y; Koike H; Nishio S
J Cardiovasc Pharmacol; 1995 Oct; 26(4):603-7. PubMed ID: 8569222
[TBL] [Abstract][Full Text] [Related]
50. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Barbault F; Maurel F
J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
[TBL] [Abstract][Full Text] [Related]
51. Pathway of urokinase-type plasminogen activator induction in the T47D and LLC-PK1 cell lines.
Jans DA; Dierks-Ventling C; Hemmings BA
Exp Cell Res; 1987 Sep; 172(1):76-83. PubMed ID: 3653259
[TBL] [Abstract][Full Text] [Related]
52. Protective effect of beraprost sodium, a new chemically stable prostacyclin analogue, against the deterioration of baroreceptor reflex following transient global cerebral ischaemia in dogs.
Kurihara J; Sahara T; Kato H
Br J Pharmacol; 1990 Jan; 99(1):91-6. PubMed ID: 2110014
[TBL] [Abstract][Full Text] [Related]
53. Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells.
Pearson D; Altus MS; Horiuchi A; Nagamine Y
Biochem Biophys Res Commun; 1987 Feb; 143(1):329-36. PubMed ID: 3827925
[TBL] [Abstract][Full Text] [Related]
54. A stable prostacyclin analog, beraprost sodium, attenuates platelet accumulation and preservation-reperfusion injury of isografts in a rat model of lung transplantation.
Okada Y; Marchevsky AM; Kass RM; Matloff JM; Jordan SC
Transplantation; 1998 Nov; 66(9):1132-6. PubMed ID: 9825806
[TBL] [Abstract][Full Text] [Related]
55. Cyclic AMP increases thrombomodulin expression on membrane surface of cultured human umbilical vein endothelial cells.
Ishii H; Kizaki K; Uchiyama H; Horie S; Kazama M
Thromb Res; 1990 Sep; 59(5):841-50. PubMed ID: 1700492
[TBL] [Abstract][Full Text] [Related]
56. Effect of beraprost, a stable prostacyclin analogue, on red blood cell deformability impairment in the presence of hypercholesterolemia in rabbits.
Hayashi J; Ishida N; Sato H; Hata Y; Saito T
J Cardiovasc Pharmacol; 1996 Apr; 27(4):527-31. PubMed ID: 8847869
[TBL] [Abstract][Full Text] [Related]
57. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
Billström A; Hartley-Asp B; Lecander I; Batra S; Astedt B
Int J Cancer; 1995 May; 61(4):542-7. PubMed ID: 7759160
[TBL] [Abstract][Full Text] [Related]
58. Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture.
Kamio K; Sato T; Liu X; Sugiura H; Togo S; Kobayashi T; Kawasaki S; Wang X; Mao L; Ahn Y; Holz O; Magnussen H; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2008 Jun; 294(6):L1226-32. PubMed ID: 18424619
[TBL] [Abstract][Full Text] [Related]
59. Activation of cAMP-dependent protein kinase alters the chromatin structure of the urokinase-type plasminogen activator gene promoter.
Lee JS; Catanzariti L; Hemmings BA; Kiefer B; Nagamine Y
Nucleic Acids Res; 1994 Feb; 22(4):569-75. PubMed ID: 8127705
[TBL] [Abstract][Full Text] [Related]
60. Prostacyclin effects on adenylate cyclase in platelets and vascular smooth muscle: interaction with an inhibitory receptor or partial agonism?
Rovati GE; Giovanazzi S; Negretti A; Nicosia S
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():263-5. PubMed ID: 7732849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
